IL231732A - Methods for Therapeutic Monitoring of Nitrogen Purification Drugs - Google Patents
Methods for Therapeutic Monitoring of Nitrogen Purification DrugsInfo
- Publication number
- IL231732A IL231732A IL231732A IL23173214A IL231732A IL 231732 A IL231732 A IL 231732A IL 231732 A IL231732 A IL 231732A IL 23173214 A IL23173214 A IL 23173214A IL 231732 A IL231732 A IL 231732A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- nitrogen scavenging
- therapeutic monitoring
- scavenging drugs
- drugs
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000012544 monitoring process Methods 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 title 1
- 230000002000 scavenging effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
- G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
- G01N31/221—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators for investigating pH value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/173845—Amine and quaternary ammonium
- Y10T436/175383—Ammonia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Ecology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542100P | 2011-09-30 | 2011-09-30 | |
| US201161564668P | 2011-11-29 | 2011-11-29 | |
| PCT/US2012/028620 WO2013048558A2 (en) | 2011-09-30 | 2012-03-09 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL231732A0 IL231732A0 (en) | 2014-05-28 |
| IL231732A true IL231732A (en) | 2017-09-28 |
Family
ID=47892277
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL231732A IL231732A (en) | 2011-09-30 | 2014-03-27 | Methods for Therapeutic Monitoring of Nitrogen Purification Drugs |
| IL254134A IL254134A0 (en) | 2011-09-30 | 2017-08-24 | Methods for therapeutic monitoring of nitrogen purging drugs |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL254134A IL254134A0 (en) | 2011-09-30 | 2017-08-24 | Methods for therapeutic monitoring of nitrogen purging drugs |
Country Status (25)
| Country | Link |
|---|---|
| US (21) | US8404215B1 (enExample) |
| EP (2) | EP3263102A1 (enExample) |
| JP (2) | JP6073898B2 (enExample) |
| KR (2) | KR20140094517A (enExample) |
| CN (2) | CN104039358A (enExample) |
| AU (2) | AU2012316750B2 (enExample) |
| BR (1) | BR112014007357B1 (enExample) |
| CA (1) | CA2850391A1 (enExample) |
| CL (1) | CL2014000783A1 (enExample) |
| CY (1) | CY1119028T1 (enExample) |
| DK (1) | DK2760479T3 (enExample) |
| ES (1) | ES2629859T3 (enExample) |
| HR (1) | HRP20171063T1 (enExample) |
| HU (1) | HUE035220T2 (enExample) |
| IL (2) | IL231732A (enExample) |
| LT (1) | LT2760479T (enExample) |
| MX (2) | MX366197B (enExample) |
| PL (1) | PL2760479T3 (enExample) |
| PT (1) | PT2760479T (enExample) |
| RS (1) | RS56196B1 (enExample) |
| SG (1) | SG11201400781TA (enExample) |
| SI (1) | SI2760479T1 (enExample) |
| SM (1) | SMT201700321T1 (enExample) |
| WO (1) | WO2013048558A2 (enExample) |
| ZA (1) | ZA201401851B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012316750B2 (en) | 2011-09-30 | 2017-08-31 | Immedica Pharma Ab | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| JP6234436B2 (ja) * | 2012-04-20 | 2017-11-22 | ホライゾン セラピューティクス，エルエルシー | フェニル酢酸プロドラッグの治療モニタリングの方法 |
| HK1210699A1 (en) * | 2012-11-21 | 2016-05-06 | Horizon Therapeutics, Inc. | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| US20150094278A1 (en) * | 2013-09-30 | 2015-04-02 | Hyperion Therapeutics, Inc. | Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy |
| SI2986325T1 (sl) | 2013-10-14 | 2020-02-28 | Immedica Pharma Ab | Postopki zdravljenja motenj ciklusa sečnine |
| EP3782610A1 (en) | 2013-11-14 | 2021-02-24 | Ultragenyx Pharmaceutical Inc. | Solid compositions of triglycerides and uses tehreof |
| CA2946422C (en) | 2014-04-30 | 2019-03-05 | The Johns Hopkins University | Dendrimer compositions and their use in treatment of diseases of the eye |
| ES2748294T3 (es) * | 2014-06-04 | 2020-03-16 | Immedica Pharma Ab | Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre |
| EP3180031A1 (en) | 2014-08-13 | 2017-06-21 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| JP7088473B2 (ja) | 2015-10-29 | 2022-06-21 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法 |
| WO2017147193A1 (en) * | 2016-02-22 | 2017-08-31 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| JP6752748B2 (ja) | 2017-03-30 | 2020-09-09 | 住友重機械工業株式会社 | 減速装置 |
| CA3068041C (en) * | 2017-07-03 | 2024-06-25 | Abbott Laboratories | Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood |
| EP3672620A1 (en) * | 2017-08-22 | 2020-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
| CA3163892A1 (en) | 2019-12-04 | 2021-06-10 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to the eye |
| CA3184989A1 (en) * | 2020-07-07 | 2022-01-13 | Christopher D. Schelling | Methods of administering taste masked phenylbutyrate and compositions therefor |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1004595A (en) | 1911-05-25 | 1911-10-03 | Sargents Sons Corp C G | Carrier for washing-bowls. |
| US1018300A (en) | 1911-06-12 | 1912-02-20 | John Davidson | Condensing steam-engine. |
| US3686238A (en) | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| CA2212047C (en) | 1995-02-07 | 2010-11-16 | Saul W. Brusilow | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
| DE19805854C1 (de) | 1998-02-13 | 1999-05-12 | Claas Usines France | Schalteinrichtung für Schneidmesser |
| US6219567B1 (en) * | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
| IT1317073B1 (it) | 2000-12-12 | 2003-05-26 | Mini Ricerca Scient Tecnolog | Esteri dell'acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico. |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US6825384B1 (en) | 2004-01-29 | 2004-11-30 | The Nutrasweet Company | Bromine free TEMPO based catalyst system for oxidation of primary and secondary alcohols using NaOCl as an oxidant |
| US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
| CN1778963A (zh) * | 2004-11-23 | 2006-05-31 | 苏州艾杰生物科技有限公司 | 血氨含量测定方法及血氨诊断试剂盒 |
| MX2007006171A (es) * | 2004-11-26 | 2007-10-08 | Ucl Business Plc | Composiciones que comprenden ornitina y acetato. |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| US20100016207A1 (en) | 2005-11-10 | 2010-01-21 | Wurtman Richard J | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid |
| US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
| JP5468015B2 (ja) | 2008-01-08 | 2014-04-09 | アクセリア ファーマシューティカルズ | 抗菌ペプチド系に対する作動薬 |
| PL3133396T3 (pl) | 2008-04-29 | 2019-03-29 | Horizon Therapeutics, Llc | Sposób leczenia z zastosowaniem leków wychwytujących amoniak |
| WO2009145323A1 (ja) | 2008-05-30 | 2009-12-03 | 日産化学工業株式会社 | 多環式化合物を用いるアルコールの酸化方法 |
| PT3133396T (pt) | 2008-08-29 | 2018-12-07 | Immedica Pharma Ab | Métodos de tratamento utilizando fármacos eliminadores de amoníaco |
| CA2735234A1 (en) | 2008-08-29 | 2010-03-04 | Ucyclyd Pharma, Inc. | Dosing and monitoring patients on nitrogen-scavenging drugs |
| BR112012001465B1 (pt) | 2009-07-24 | 2021-08-31 | Baylor College Of Medicine | Uso de um fenilbutirato, sal, éster ou pró-fármaco do mesmo |
| JP5763638B2 (ja) | 2010-07-16 | 2015-08-12 | 第一三共株式会社 | アルコール類の酸化方法 |
| JP6049619B2 (ja) | 2010-08-31 | 2016-12-21 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ナノヒドロキシアパタイトを含む多孔質多糖足場、及び骨形成のための使用 |
| AU2012316750B2 (en) | 2011-09-30 | 2017-08-31 | Immedica Pharma Ab | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| EP2607366A1 (en) | 2011-12-21 | 2013-06-26 | Lunamed AG | Glycerol phenyl butyrate esters |
| JP6234436B2 (ja) | 2012-04-20 | 2017-11-22 | ホライゾン セラピューティクス，エルエルシー | フェニル酢酸プロドラッグの治療モニタリングの方法 |
| HK1210699A1 (en) | 2012-11-21 | 2016-05-06 | Horizon Therapeutics, Inc. | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| CN103304402B (zh) | 2013-05-24 | 2015-04-22 | 苏州诚和医药化学有限公司 | 一种制备4-苯-1-丁酸的方法 |
| US20150094278A1 (en) | 2013-09-30 | 2015-04-02 | Hyperion Therapeutics, Inc. | Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy |
| SI2986325T1 (sl) | 2013-10-14 | 2020-02-28 | Immedica Pharma Ab | Postopki zdravljenja motenj ciklusa sečnine |
| WO2015063659A1 (en) | 2013-10-30 | 2015-05-07 | Lupin Limited | Process for the preparation of glycerol phenylbutyrate |
| ES2748294T3 (es) | 2014-06-04 | 2020-03-16 | Immedica Pharma Ab | Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre |
| WO2017147193A1 (en) | 2016-02-22 | 2017-08-31 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US20190076383A1 (en) | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
-
2012
- 2012-03-09 AU AU2012316750A patent/AU2012316750B2/en active Active
- 2012-03-09 JP JP2014533519A patent/JP6073898B2/ja active Active
- 2012-03-09 CA CA2850391A patent/CA2850391A1/en not_active Withdrawn
- 2012-03-09 KR KR1020147011146A patent/KR20140094517A/ko not_active Ceased
- 2012-03-09 KR KR1020187020761A patent/KR102019000B1/ko active Active
- 2012-03-09 CN CN201280048373.5A patent/CN104039358A/zh active Pending
- 2012-03-09 ES ES12835407.3T patent/ES2629859T3/es active Active
- 2012-03-09 DK DK12835407.3T patent/DK2760479T3/en active
- 2012-03-09 CN CN201710239760.1A patent/CN107271696A/zh active Pending
- 2012-03-09 SM SM20170321T patent/SMT201700321T1/it unknown
- 2012-03-09 EP EP17168773.4A patent/EP3263102A1/en not_active Withdrawn
- 2012-03-09 BR BR112014007357-0A patent/BR112014007357B1/pt active IP Right Grant
- 2012-03-09 RS RS20170682A patent/RS56196B1/sr unknown
- 2012-03-09 MX MX2014003854A patent/MX366197B/es active IP Right Grant
- 2012-03-09 PT PT128354073T patent/PT2760479T/pt unknown
- 2012-03-09 US US13/417,137 patent/US8404215B1/en active Active
- 2012-03-09 LT LTEP12835407.3T patent/LT2760479T/lt unknown
- 2012-03-09 HU HUE12835407A patent/HUE035220T2/hu unknown
- 2012-03-09 SG SG11201400781TA patent/SG11201400781TA/en unknown
- 2012-03-09 HR HRP20171063TT patent/HRP20171063T1/hr unknown
- 2012-03-09 WO PCT/US2012/028620 patent/WO2013048558A2/en not_active Ceased
- 2012-03-09 PL PL12835407T patent/PL2760479T3/pl unknown
- 2012-03-09 EP EP12835407.3A patent/EP2760479B1/en active Active
- 2012-03-09 SI SI201230985A patent/SI2760479T1/sl unknown
-
2013
- 2013-02-22 US US13/775,000 patent/US9095559B2/en active Active
-
2014
- 2014-03-12 ZA ZA2014/01851A patent/ZA201401851B/en unknown
- 2014-03-27 IL IL231732A patent/IL231732A/en active IP Right Grant
- 2014-03-28 CL CL2014000783A patent/CL2014000783A1/es unknown
- 2014-03-28 MX MX2019006900A patent/MX2019006900A/es unknown
-
2015
- 2015-08-03 US US14/816,674 patent/US9254278B2/en active Active
- 2015-12-03 US US14/958,259 patent/US9326966B2/en active Active
-
2016
- 2016-03-18 US US15/074,691 patent/US20160199333A1/en not_active Abandoned
- 2016-03-18 US US15/074,666 patent/US20160202240A1/en not_active Abandoned
- 2016-03-18 US US15/074,716 patent/US20160199334A1/en not_active Abandoned
- 2016-03-18 US US15/074,625 patent/US20160199332A1/en not_active Abandoned
-
2017
- 2017-01-05 JP JP2017000550A patent/JP6425746B2/ja active Active
- 2017-03-13 US US15/457,643 patent/US9999608B2/en active Active
- 2017-06-28 CY CY20171100688T patent/CY1119028T1/el unknown
- 2017-08-24 IL IL254134A patent/IL254134A0/en unknown
- 2017-08-25 US US15/687,118 patent/US9962358B2/en active Active
- 2017-08-25 US US15/687,132 patent/US9962359B2/en active Active
- 2017-09-08 US US15/699,209 patent/US20180021293A1/en not_active Abandoned
- 2017-10-23 AU AU2017251691A patent/AU2017251691A1/en not_active Abandoned
-
2018
- 2018-04-03 US US15/944,422 patent/US10183003B2/en active Active
- 2018-04-03 US US15/944,411 patent/US10183002B2/en active Active
- 2018-04-03 US US15/944,432 patent/US10183005B2/en active Active
- 2018-04-03 US US15/944,398 patent/US10045958B1/en active Active
- 2018-04-03 US US15/944,428 patent/US10183004B2/en active Active
- 2018-04-03 US US15/944,416 patent/US10045959B1/en active Active
- 2018-05-15 US US15/980,376 patent/US10183006B2/en active Active
- 2018-11-16 US US16/194,061 patent/US10617665B2/en active Active
-
2020
- 2020-03-10 US US16/814,549 patent/US20210000784A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254134A0 (en) | Methods for therapeutic monitoring of nitrogen purging drugs | |
| IL276761A (en) | Methods of inducing coma | |
| IL227465A0 (en) | Supported device and methods of use | |
| EP2739144A4 (en) | COMPOUNDS AND ITS THERAPEUTIC USE | |
| EP2720719A4 (en) | METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS | |
| EP2717855A4 (en) | PROCESSING METHODS | |
| IL237138A0 (en) | Methods of administration of pirfenidone therapy | |
| ZA201405248B (en) | Anesthetic compounds and related methods of use | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| SG11201504372UA (en) | A method of purifying therapeutic proteins | |
| EP2745235A4 (en) | METHOD FOR REPOSITIONING MEDICATION | |
| IL234813A0 (en) | Methods for increasing the efficacy of cd37-based therapy | |
| ZA201403739B (en) | Methods of treatment with deferiprone | |
| EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
| ZA201502595B (en) | Therapeutic methods | |
| EP2726079A4 (en) | METHOD OF ADMINISTRATION AND TREATMENT | |
| GB201016864D0 (en) | Therapeutic methods | |
| GB201206306D0 (en) | Therapeutic apparatus | |
| GB201112739D0 (en) | Production and administration of therapeutic agents | |
| GB201109737D0 (en) | Methods of treatment | |
| GB201110602D0 (en) | Methods of treatment | |
| GB201104632D0 (en) | Use of medicament | |
| SG10201911709RA (en) | A method of purifying therapeutic proteins | |
| GB201019936D0 (en) | Therapeutic method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |